BIIB vs MLM Comparison

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Martin Marietta is a leading US producer of construction aggregates, having produced roughly 200 million tons in 2025. Its aggregate reserves represent approximately 85 years of supply at 2025 production levels. Over the past several years, the company has increased its exposure to aggregates while reducing its presence in cement and downstream businesses such as concrete and asphalt. More recently, Martin Marietta expanded into an aggregate-adjacent business through its acquisition of Lhoist North America, the largest US producer of lime. The company operates across 28 states, with smaller operations in Canada and the Bahamas.